Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Model-informed approach to support pediatric dosing for the pan-PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors.
Morcos PN, Schlender J, Burghaus R, Moss J, Lloyd A, Childs BH, Macy ME, Reid JM, Chung J, Garmann D. Morcos PN, et al. Among authors: garmann d. Clin Transl Sci. 2023 Jul;16(7):1197-1209. doi: 10.1111/cts.13523. Epub 2023 Apr 18. Clin Transl Sci. 2023. PMID: 37042099 Free PMC article. Clinical Trial.
NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure.
Schmitt W, Rühs H, Burghaus R, Diedrich C, Duwal S, Eissing T, Garmann D, Meyer M, Ploeger B, Lippert J. Schmitt W, et al. Among authors: garmann d. Clin Pharmacol Ther. 2021 Aug;110(2):498-507. doi: 10.1002/cpt.2222. Epub 2021 Mar 27. Clin Pharmacol Ther. 2021. PMID: 33630302 Free PMC article.
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab.
Morcos PN, Moss J, Austin R, Hiemeyer F, Zinzani PL, Beckert V, Mongay Soler L, Childs BH, Garmann D. Morcos PN, et al. Among authors: garmann d. CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1666-1686. doi: 10.1002/psp4.13000. Epub 2023 Jun 30. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 37389853 Free PMC article.
Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Snelder N, et al. Among authors: garmann d. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x. Clin Pharmacokinet. 2020. PMID: 31583611 Free PMC article. Clinical Trial.
34 results